Phase 2 N=12 Podocyte Retinoids
Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Multiple Myeloma · Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Proportion of Patients From Whom a Total Number of CD34+ Cells ≥5.0 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions — 0.50000; 0.9167; 0.9167…
Phase 2 N=40 Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme
Glioblastoma Multiforme of the Brain
Primary: Number of Participants With Objective Response — 1; 1; 5; 19 Participants
Phase 2 N=274 Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
Actinic Keratosis
Primary: Complete Clearance Rate — 16; 15; 10; 12 AK Fields
Phase 2 N=37 Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Non Small Cell Lung Cancer
Primary: Progression Free Survival at 3 Months — 50.4 percentage of participants
Phase 2 N=35 Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Undifferentiated Carcinoma · Gastric Adenocarcinoma
Primary: Overall Response Rate — 26 percentage of participants
Phase 2 N=52 Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance
Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer
Primary: Change in Ki67 Expression in Tumors — -40 percentage change in Ki67 — p=0.0001
Phase 2 N=129 Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation
Atrial Fibrillation
Primary: Freedom From Any Atrial Arrhythmias — 24; 23 Participants — p=.83
Phase 2 N=81 Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia
Iron Deficiency · Fibromyalgia
Primary: Proportion of Patients With a ≥13 Point Improvement in FIQR Score — 30; 26 Participants
Phase 2 N=29 The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor
Obstetric Labour, Premature
Primary: Number of Participants With Vital Sign Values of Potential Clinical Concern — 2; 4; 0; 3 Participants
Phase 2 N=342 A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
HIV Infections
Primary: Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I) — 90.0; 93.0; 71.4; 85.4 Percentage of participants
Phase 2 N=204 Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants
Evaluation of a Rotavirus Vaccine
Primary: Number of Participants With Vaccine Induced Reactions — 3; 8; 4; 6 Participants
Phase 2 N=28 Subacromial Corticosteroid Injection for Hemiplegic Shoulder Pain
Shoulder Pain
Primary: BPI 12 (Brief Pain Inventory, Question 12) Pain Questionnaire — -1.7; -2.2; -4.7 units on a scale — p=0.16
Phase 2 N=194 Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)
Diabetes Mellitus, Type 2 · Hypertension
Primary: Baseline 24-hour Average Systolic Blood Pressure (SBP) — 136.11; 133.13; 135.08; 135.59 mmHg
Phase 2 N=322 Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
Influenza
Primary: Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis — 60; 53; 45; 36 Participants